BeiGene Stock Price, News & Analysis (NASDAQ:BGNE)

$84.18 -0.51 (-0.60 %)
(As of 11/20/2017 04:12 AM ET)
Previous Close$84.69
Today's Range$82.50 - $84.44
52-Week Range$26.43 - $118.95
Volume152,500 shs
Average Volume191,624 shs
Market Capitalization$3.82741 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.52

About BeiGene (NASDAQ:BGNE)

BeiGene logoBeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:BGNE
  • CUSIP: N/A
  • Web: www.beigene.com
Debt:
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 9.33%
  • Quick Ratio: 9.27%
Sales & Book Value:
  • Annual Sales: $1.07 million
  • Price / Sales: 3,577.26
  • Book Value: $11.20 per share
  • Price / Book: 7.52
Profitability:
  • Trailing EPS: ($1.30)
  • Net Income: ($119,210,000.00)
  • Return on Equity: -7.40%
  • Return on Assets: -5.44%
Misc:
  • Employees: 322
  • Outstanding Shares: 45,470,000
 

Frequently Asked Questions for BeiGene (NASDAQ:BGNE)

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings results on Monday, November, 13th. The company reported $2.54 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $2.31. The company earned $220.21 million during the quarter, compared to analysts' expectations of $1.55 million. During the same period in the previous year, the company posted ($1.08) earnings per share. View BeiGene's Earnings History.

Where is BeiGene's stock going? Where will BeiGene's stock price be in 2017?

7 equities research analysts have issued twelve-month target prices for BeiGene's shares. Their predictions range from $81.00 to $120.00. On average, they anticipate BeiGene's stock price to reach $93.00 in the next twelve months. View Analyst Ratings for BeiGene.

What are Wall Street analysts saying about BeiGene stock?

Here are some recent quotes from research analysts about BeiGene stock:

  • 1. Cowen and Company analysts commented, "SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials." (11/14/2017)
  • 2. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (11/13/2017)
  • 3. Maxim Group analysts commented, "BeiGene reported 1Q17 results. The company spent $52.5M during the quarter. The increased operating expenses were driven by clinical expansion to pivotal studies. Net loss for the quarter was $50.6M or ($1.27) per share. BeiGene ended the period with $327M of liquidity on the balance sheet. We model rising R&D expenses with clinical advances." (5/11/2017)

Who are some of BeiGene's key competitors?

Who are BeiGene's key executives?

BeiGene's management team includes the folowing people:

  • John V Oyler, Chairman of the Board, Chief Executive Officer, Founder (Age 48)
  • Howard Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 52)
  • Wendy Yan, Senior Vice President, Head of Regulatory Affairs (Age 50)
  • Jason Yang M.D.Suffix is Ph.D., Senior Vice President, Head of Clinical Development (Age 51)
  • Timothy Y. Chen, Director (Age 59)
  • Donald W. Glazer, Director (Age 71)
  • Michael J. Goller, Director (Age 40)
  • Ranjeev Krishana, Director (Age 41)
  • Xiaodong Wang Ph.D., Director (Age 52)

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Who owns BeiGene stock?

BeiGene's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include CELGENE CORP (5.60%), Orbimed Advisors LLC (3.28%), Canada Pension Plan Investment Board (1.51%), Brown Advisory Inc. (0.83%), Janus Henderson Group PLC (0.81%) and Myriad Asset Management Ltd. (0.60%). Company insiders that own BeiGene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for BeiGene.

Who sold BeiGene stock? Who is selling BeiGene stock?

BeiGene's stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Brown Advisory Inc., Myriad Asset Management Ltd., Ariose Capital Management Ltd, University of Notre Dame DU Lac and State of New Jersey Common Pension Fund D. Company insiders that have sold BeiGene company stock in the last year include Amy C Peterson, Donald W Glazer, John Oyler and Xiaodong Wang. View Insider Buying and Selling for BeiGene.

Who bought BeiGene stock? Who is buying BeiGene stock?

BeiGene's stock was acquired by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Janus Henderson Group PLC, California Public Employees Retirement System, Orbimed Advisors LLC, Belpointe Asset Management LLC, First Trust Advisors LP, Westpac Banking Corp and Alps Advisors Inc.. Company insiders that have bought BeiGene stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Ruirong Yuan and Thomas Malley. View Insider Buying and Selling for BeiGene.

How do I buy BeiGene stock?

Shares of BeiGene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BeiGene's stock price today?

One share of BeiGene stock can currently be purchased for approximately $84.18.

How big of a company is BeiGene?

BeiGene has a market capitalization of $3.82741 billion and generates $1.07 million in revenue each year. The company earns ($119,210,000.00) in net income (profit) each year or ($1.30) on an earnings per share basis. BeiGene employs 322 workers across the globe.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]


MarketBeat Community Rating for BeiGene (NASDAQ BGNE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for BeiGene (NASDAQ:BGNE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $93.00 (10.48% upside)

Consensus Price Target History for BeiGene (NASDAQ:BGNE)

Price Target History for BeiGene (NASDAQ:BGNE)

Analysts' Ratings History for BeiGene (NASDAQ:BGNE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Maxim GroupSet Price TargetBuy$120.00N/AView Rating Details
11/14/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/14/2017Robert W. BairdReiterated RatingOutperform -> Neutral$58.00 -> $83.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$87.00 -> $95.00N/AView Rating Details
8/15/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$43.00 -> $86.00LowView Rating Details
8/7/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$81.00HighView Rating Details
6/1/2017William BlairReiterated RatingOutperformLowView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for BeiGene (NASDAQ:BGNE)

Earnings by Quarter for BeiGene (NASDAQ:BGNE)

Earnings History by Quarter for BeiGene (NASDAQ BGNE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3$0.23$2.54$1.55 million$220.21 millionViewN/AView Earnings Details
3/22/2017Q4($0.86)($1.05)$3.75 million$1.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.78)($1.08)$1.88 millionViewN/AView Earnings Details
8/10/2016Q2($0.68)($0.73)$2.08 million$0.40 millionViewN/AView Earnings Details
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BeiGene (NASDAQ:BGNE)
2017 EPS Consensus Estimate: ($4.57)
2018 EPS Consensus Estimate: ($7.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($1.20)($1.20)($1.20)
Q3 20171($1.49)($1.49)($1.49)
Q4 20171($1.88)($1.88)($1.88)
Q1 20181($2.11)($2.11)($2.11)
Q2 20181($2.14)($2.14)($2.14)
Q3 20181($2.18)($2.18)($2.18)
Q4 20181($1.12)($1.12)($1.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BeiGene (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BeiGene (NASDAQ BGNE)

Insider Ownership Percentage: 19.90%
Institutional Ownership Percentage: 57.07%
Insider Trades by Quarter for BeiGene (NASDAQ:BGNE)
Insider Trades by Quarter for BeiGene (NASDAQ:BGNE)

Insider Trades by Quarter for BeiGene (NASDAQ BGNE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017John OylerCEOSell150,957$80.50$12,152,038.50View SEC Filing  
11/13/2017Amy C PetersonCMOSell3,601$82.96$298,738.96View SEC Filing  
11/13/2017John OylerCEOSell25,054$83.06$2,080,985.24View SEC Filing  
8/11/2017Bros. Advisors Lp BakerDirectorBuy176,056$71.00$12,499,976.00View SEC Filing  
7/12/2017Xiaodong WangDirectorSell20,000$72.44$1,448,800.00View SEC Filing  
7/10/2017Donald W GlazerDirectorSell10,810$72.15$779,941.50View SEC Filing  
7/6/2017John OylerCEOSell219,400$64.82$14,221,508.00View SEC Filing  
6/28/2017Xiaodong WangDirectorSell35,000$44.95$1,573,250.00View SEC Filing  
6/23/2017John OylerCEOSell98,500$44.16$4,349,760.00View SEC Filing  
6/2/2017Xiaodong WangDirectorSell5,539$40.00$221,560.00View SEC Filing  
5/4/2017Xiaodong WangDirectorSell14,461$40.80$590,008.80View SEC Filing  
5/1/2017John OylerCEOSell36,149$40.47$1,462,950.03View SEC Filing  
4/5/2017Xiaodong WangDirectorSell11,650$36.83$429,069.50View SEC Filing  
3/24/2017Xiaodong WangDirectorSell38,107$36.96$1,408,434.72View SEC Filing  
3/20/2017John OylerCEOSell31,989$39.39$1,260,046.71View SEC Filing  
3/10/2017Xiaodong WangDirectorSell36,892$39.89$1,471,621.88View SEC Filing  
3/6/2017John OylerCEOSell108,999$40.91$4,459,149.09View SEC Filing  
2/27/2017Xiaodong WangDirectorSell38,351$38.19$1,464,624.69View SEC Filing  
2/21/2017John OylerCEOSell64,963$40.55$2,634,249.65View SEC Filing  
11/23/2016Thomas MalleyDirectorBuy30,000$32.00$960,000.00View SEC Filing  
11/18/2016Bros. Advisors Lp BakerDirectorBuy1,760,495$32.00$56,335,840.00View SEC Filing  
9/28/2016Donald W GlazerDirectorSell41,463$30.66$1,271,255.58View SEC Filing  
9/27/2016Donald W GlazerDirectorSell47,149$29.61$1,396,081.89View SEC Filing  
9/23/2016Donald W GlazerDirectorSell36,443$31.02$1,130,461.86View SEC Filing  
9/21/2016Donald W GlazerDirectorSell67,252$31.42$2,113,057.84View SEC Filing  
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.00View SEC Filing  
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BeiGene (NASDAQ BGNE)

Source:
DateHeadline
Maxim Group Analysts Give BeiGene, Ltd. (BGNE) a $120.00 Price TargetMaxim Group Analysts Give BeiGene, Ltd. (BGNE) a $120.00 Price Target
www.americanbankingnews.com - November 19 at 9:36 PM
$23.00 Million in Sales Expected for BeiGene, Ltd. (BGNE) This Quarter$23.00 Million in Sales Expected for BeiGene, Ltd. (BGNE) This Quarter
www.americanbankingnews.com - November 18 at 11:58 AM
Q4 2017 Earnings Estimate for BeiGene, Ltd. (BGNE) Issued By William BlairQ4 2017 Earnings Estimate for BeiGene, Ltd. (BGNE) Issued By William Blair
www.americanbankingnews.com - November 17 at 10:40 PM
$0.86 EPS Expected for BeiGene, Ltd. (BGNE) This Quarter$0.86 EPS Expected for BeiGene, Ltd. (BGNE) This Quarter
www.americanbankingnews.com - November 16 at 3:08 AM
BeiGene, Ltd. (BGNE) CMO Amy C. Peterson Sells 3,601 SharesBeiGene, Ltd. (BGNE) CMO Amy C. Peterson Sells 3,601 Shares
www.americanbankingnews.com - November 15 at 10:29 PM
BeiGene, Ltd. (BGNE) CEO John Oyler Sells 25,054 SharesBeiGene, Ltd. (BGNE) CEO John Oyler Sells 25,054 Shares
www.americanbankingnews.com - November 15 at 10:26 PM
John Oyler Sells 150,957 Shares of BeiGene, Ltd. (BGNE) StockJohn Oyler Sells 150,957 Shares of BeiGene, Ltd. (BGNE) Stock
www.americanbankingnews.com - November 15 at 10:26 PM
BeiGene, Ltd. (BGNE) Stock Rating Reaffirmed by Cowen and CompanyBeiGene, Ltd. (BGNE) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - November 14 at 11:03 PM
BeiGene, Ltd. (BGNE) Rating Lowered to Neutral at Robert W. BairdBeiGene, Ltd. (BGNE) Rating Lowered to Neutral at Robert W. Baird
www.americanbankingnews.com - November 14 at 8:46 AM
BeiGene, Ltd. (BGNE) Announces  Earnings ResultsBeiGene, Ltd. (BGNE) Announces Earnings Results
www.americanbankingnews.com - November 14 at 8:20 AM
BeiGene Reports Third Quarter 2017 Financial ResultsBeiGene Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 1:08 AM
BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111
finance.yahoo.com - November 14 at 1:08 AM
BeiGene, Ltd. (BGNE) Rating Lowered to Sell at Zacks Investment ResearchBeiGene, Ltd. (BGNE) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 13 at 8:30 PM
BeiGene, Ltd. (BGNE) Receives Average Rating of "Buy" from AnalystsBeiGene, Ltd. (BGNE) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 12 at 12:00 PM
BeiGene Reaches Analyst Target PriceBeiGene Reaches Analyst Target Price
www.nasdaq.com - November 1 at 5:08 PM
BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual MeetingBeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 5:08 PM
BeiGene, Ltd. (BGNE) to Release Quarterly Earnings on WednesdayBeiGene, Ltd. (BGNE) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:08 AM
Developments in Chinas Healthcare IndustryDevelopments in China's Healthcare Industry
www.bizjournals.com - October 27 at 11:52 PM
BeiGene, Ltd. (BGNE) Given Average Rating of "Buy" by BrokeragesBeiGene, Ltd. (BGNE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 18 at 12:48 PM
BeiGenes (BGNE) Overweight Rating Reaffirmed at Morgan StanleyBeiGene's (BGNE) Overweight Rating Reaffirmed at Morgan Stanley
www.americanbankingnews.com - October 7 at 1:04 PM
[$$] Celgene Invests in Acceleron, BeiGene[$$] Celgene Invests in Acceleron, BeiGene
finance.yahoo.com - October 2 at 11:56 AM
Celgene Invests in Acceleron, BeiGene - BarronsCelgene Invests in Acceleron, BeiGene - Barron's
www.barrons.com - September 30 at 6:36 PM
BeiGene, Ltd. (BGNE) PT Raised to $120 at Maxim Group - StreetInsider.comBeiGene, Ltd. (BGNE) PT Raised to $120 at Maxim Group - StreetInsider.com
www.streetinsider.com - September 30 at 6:36 PM
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCOBeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO
globenewswire.com - September 28 at 9:48 PM
BeiGene (BGNE) Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at CSCOBeiGene (BGNE) Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at CSCO
www.streetinsider.com - September 28 at 9:48 PM
Maxim Group Reiterates Buy Rating for BeiGene, Ltd. (BGNE)Maxim Group Reiterates Buy Rating for BeiGene, Ltd. (BGNE)
www.americanbankingnews.com - September 28 at 2:30 PM
BeiGene (BGNE) vs. The Competition Head-To-Head AnalysisBeiGene (BGNE) vs. The Competition Head-To-Head Analysis
www.americanbankingnews.com - September 24 at 2:28 PM
BeiGene, Ltd. (BGNE) Receives Average Rating of "Buy" from BrokeragesBeiGene, Ltd. (BGNE) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 23 at 10:42 AM
BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical OncologyBeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology
finance.yahoo.com - September 21 at 4:17 PM
BeiGene, Ltd. Forecasted to Post Q3 2017 Earnings of ($1.49) Per Share (BGNE)BeiGene, Ltd. Forecasted to Post Q3 2017 Earnings of ($1.49) Per Share (BGNE)
www.americanbankingnews.com - September 13 at 8:00 AM
Checkpoint Inhibitors Are Hot, and CKPT Has Something in the OvenCheckpoint Inhibitors Are Hot, and CKPT Has Something in the Oven
finance.yahoo.com - September 12 at 4:45 PM
[$$] Celgene Launch to Lift BeiGene[$$] Celgene Launch to Lift BeiGene
finance.yahoo.com - September 12 at 4:45 PM
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 CongressBeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress
finance.yahoo.com - September 11 at 5:09 PM
Maxim Group Reaffirms Buy Rating for BeiGene, Ltd. (BGNE)Maxim Group Reaffirms Buy Rating for BeiGene, Ltd. (BGNE)
www.americanbankingnews.com - September 11 at 3:50 PM
BeiGene (BGNE) Announces Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290BeiGene (BGNE) Announces Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290
www.streetinsider.com - September 8 at 4:55 PM
BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 CongressBeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress
finance.yahoo.com - September 8 at 4:55 PM
BGNE Crosses Above Average Analyst TargetBGNE Crosses Above Average Analyst Target
www.nasdaq.com - September 7 at 9:45 PM
BeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene CorporationBeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene Corporation
finance.yahoo.com - August 31 at 4:24 PM
BeiGene to Present at Upcoming Investor ConferencesBeiGene to Present at Upcoming Investor Conferences
finance.yahoo.com - August 30 at 5:47 PM
BeiGene, Ltd. (BGNE) Given Consensus Rating of "Buy" by BrokeragesBeiGene, Ltd. (BGNE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 29 at 10:46 AM
Beigene Ltd (BGNE) Rating Reiterated by Goldman Sachs Group, Inc. (The)Beigene Ltd (BGNE) Rating Reiterated by Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - August 15 at 10:32 PM
BeiGene, Ltd. (BGNE) Director Bros. Advisors Lp Baker Purchases 176,056 SharesBeiGene, Ltd. (BGNE) Director Bros. Advisors Lp Baker Purchases 176,056 Shares
www.americanbankingnews.com - August 14 at 4:30 PM
BeiGene (BGNE) Prices of 2.47M Public Offering at $71/ADSBeiGene (BGNE) Prices of 2.47M Public Offering at $71/ADS
www.streetinsider.com - August 12 at 4:11 PM
BeiGene (BGNE) to Offer and Sell $125M ADSsBeiGene (BGNE) to Offer and Sell $125M ADSs
www.streetinsider.com - August 11 at 3:49 AM
BeiGene Announces Pricing of $175 Million Public OfferingBeiGene Announces Pricing of $175 Million Public Offering
finance.yahoo.com - August 10 at 10:47 PM
BeiGene Reports Second Quarter 2017 Financial ResultsBeiGene Reports Second Quarter 2017 Financial Results
www.nasdaq.com - August 9 at 4:44 PM
BeiGene, Ltd. (BGNE) Receives Consensus Recommendation of "Buy" from BrokeragesBeiGene, Ltd. (BGNE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 4 at 1:02 PM
BeiGene, Ltd. (BGNE) to Release Earnings on TuesdayBeiGene, Ltd. (BGNE) to Release Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:30 AM
How WebMD Got Locked Out Of The China MarketHow WebMD Got Locked Out Of The China Market
seekingalpha.com - July 26 at 5:06 PM
BeiGene, Ltd. (BGNE) Director Xiaodong Wang Sells 20,000 SharesBeiGene, Ltd. (BGNE) Director Xiaodong Wang Sells 20,000 Shares
www.americanbankingnews.com - July 13 at 7:52 PM

Social Media

Financials

Chart

BeiGene (NASDAQ BGNE) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.